Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Denali Therapeutics stock

DNLI
US24823R1059
A2H9G8

Price

21.45
Today +/-
-0.04
Today %
-0.19 %

Denali Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Denali Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Denali Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Denali Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Denali Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Denali Therapeutics Stock Price History

DateDenali Therapeutics Price
12/20/202421.45 undefined
12/19/202421.49 undefined
12/18/202421.43 undefined
12/17/202423.22 undefined
12/16/202423.29 undefined
12/13/202422.97 undefined
12/12/202423.47 undefined
12/11/202423.87 undefined
12/10/202424.49 undefined
12/9/202424.96 undefined
12/6/202424.89 undefined
12/5/202423.32 undefined
12/4/202423.70 undefined
12/3/202423.89 undefined
12/2/202425.63 undefined
11/29/202425.00 undefined
11/27/202425.16 undefined
11/26/202424.68 undefined
11/25/202424.50 undefined

Denali Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Denali Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Denali Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Denali Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Denali Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Denali Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Denali Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Denali Therapeutics’s growth potential.

Denali Therapeutics Revenue, EBIT and net profit per share

DateDenali Therapeutics RevenueDenali Therapeutics EBITDenali Therapeutics Net Income
2029e880.86 M undefined205.74 M undefined267.17 M undefined
2028e680.22 M undefined-9.07 M undefined-9.79 M undefined
2027e408.6 M undefined-307.69 M undefined-108.63 M undefined
2026e187.24 M undefined-448.57 M undefined-340.5 M undefined
2025e54.51 M undefined-525.83 M undefined-430.64 M undefined
2024e10.48 M undefined-532.47 M undefined-409.79 M undefined
2023330.53 M undefined-196.7 M undefined-145.22 M undefined
2022108.5 M undefined-340.7 M undefined-326 M undefined
202148.7 M undefined-295.8 M undefined-290.6 M undefined
2020335.7 M undefined62.7 M undefined71.1 M undefined
201926.7 M undefined-213.2 M undefined-197.6 M undefined
2018129.2 M undefined-46.4 M undefined-36.2 M undefined
20170 undefined-90.1 M undefined-88.2 M undefined
20160 undefined-87.4 M undefined-86.7 M undefined
20150 undefined-16.7 M undefined-16.8 M undefined

Denali Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00012926335481083301054187408680880
-----79.841,188.46-85.67125.00205.56-96.97440.00246.30118.1866.6729.41
---------------
000000000000000
-16-86-88-36-19771-290-326-145-409-430-340-108-9267
-437.502.33-59.09447.22-136.04-508.4512.41-55.52182.075.13-20.93-68.24-91.67-3,066.67
82.482.487.592.695.6112.7121.5125.5137.37000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Denali Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Denali Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
201520162017201820192020202120222023
                 
0.030.180.410.460.421.470.871.341.03
00.40.51.200000
000000000
000000000
2.73.22.915.414.720.330.636.129.63
0.030.180.410.480.431.490.91.371.06
3.215.314.925.280.773.569.674.571.64
073.161.3147.939.932.7425.400
000000000
000000000
000000000
0.10.80.98.12.72.511.913.418.14
3.389.277.1181.2123.3108.7506.987.989.78
0.040.270.490.660.551.61.41.461.15
                 
48.53491.21.31.31.51.51.71.71
00.010.660.770.821.51.612.022.14
-16.9-103.5-191.7-227.9-425.6-354.4-645-971-1,116.21
0-400-400-600400-200-2,500-6,900643
000000000
0.030.250.470.550.391.150.961.041.03
1.722.71.92.61.14.82.89.48
1.66.410.518.52447.153.266.768.5
0.10.70.912.418.723.5320.3294.40
000000000
000000000
3.49.114.132.845.371.7378.3363.977.98
000000000
000000000
0.57.46.882.4113382.163.653.944.98
0.57.46.882.4113382.163.653.944.98
3.916.520.9115.2158.3453.8441.9417.8122.96
0.040.270.490.660.551.61.41.461.15
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Denali Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Denali Therapeutics's financial health and stability.

Assets

Denali Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Denali Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Denali Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Denali Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-16-86-88-36-19771-290-326-145
01378881016
000000000
043624286-23-24-289
11193472100179194168
000000000
000000000
-15-71-7650-151416-211-244-357
-3-6-2-3-17-3-8-17-12
-3-219-41-287147-623-21-141249
0-212-38-284165-620-13-123262
000000000
500000000
433002969866341931017
483002969766341931017
----1.00-----
000000000
309178-1402427-213-75-90
-18.2-78-79.546.7-169.5413.1-219.9-262.5-370.93
000000000

Denali Therapeutics stock margins

The Denali Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Denali Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Denali Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Denali Therapeutics's sales revenue. A higher gross margin percentage indicates that the Denali Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Denali Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Denali Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Denali Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Denali Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Denali Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Denali Therapeutics Margin History

Denali Therapeutics Gross marginDenali Therapeutics Profit marginDenali Therapeutics EBIT marginDenali Therapeutics Profit margin
2029e0 %23.36 %30.33 %
2028e0 %-1.33 %-1.44 %
2027e0 %-75.3 %-26.59 %
2026e0 %-239.57 %-181.85 %
2025e0 %-964.7 %-790.06 %
2024e0 %-5,083.21 %-3,912.1 %
20230 %-59.51 %-43.94 %
20220 %-314.01 %-300.46 %
20210 %-607.39 %-596.71 %
20200 %18.68 %21.18 %
20190 %-798.5 %-740.07 %
20180 %-35.91 %-28.02 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %

Denali Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Denali Therapeutics earnings per share therefore indicates how much revenue Denali Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Denali Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Denali Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Denali Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Denali Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Denali Therapeutics Revenue, EBIT and net profit per share

DateDenali Therapeutics Sales per ShareDenali Therapeutics EBIT per shareDenali Therapeutics Earnings per Share
2029e6.12 undefined0 undefined1.86 undefined
2028e4.73 undefined0 undefined-0.07 undefined
2027e2.84 undefined0 undefined-0.75 undefined
2026e1.3 undefined0 undefined-2.37 undefined
2025e0.38 undefined0 undefined-2.99 undefined
2024e0.07 undefined0 undefined-2.85 undefined
20232.41 undefined-1.43 undefined-1.06 undefined
20220.86 undefined-2.71 undefined-2.6 undefined
20210.4 undefined-2.43 undefined-2.39 undefined
20202.98 undefined0.56 undefined0.63 undefined
20190.28 undefined-2.23 undefined-2.07 undefined
20181.4 undefined-0.5 undefined-0.39 undefined
20170 undefined-1.03 undefined-1.01 undefined
20160 undefined-1.06 undefined-1.05 undefined
20150 undefined-0.2 undefined-0.2 undefined

Denali Therapeutics business model

Denali Therapeutics Inc is a biotechnology company specializing in the research and development of therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2015 by four former employees of Genentech, with the goal of finding innovative treatments for serious neurological conditions. Denali Therapeutics' business model is based on a patented platform technology that allows the company to target and deliver its drugs precisely to the brain of patients. The company utilizes "liposomes," microscopic bubbles of fat that are loaded with the drug and then transported to the brain through the bloodstream. Denali Therapeutics is divided into three divisions: development platform, therapy development, and diagnosis development. The development platform is the core business of Denali Therapeutics. Here, the company continues to develop its liposome technology to be used for various neurological diseases. The therapy development focuses on developing targeted drugs for specific neurodegenerative diseases. Denali Therapeutics collaborates closely with neurologists and other experts to develop the best possible therapies for patients. The diagnosis development aims to detect early symptoms of neurodegenerative diseases, enabling early diagnosis and treatment. Denali Therapeutics is primarily working on the development of testing methods that will allow for early detection of Alzheimer's and Parkinson's. Currently, Denali Therapeutics has several promising drugs in its pipeline. One of the most important projects is a drug for Alzheimer's disease, which is currently being tested in clinical trials. The drug targets the accumulation of beta-amyloid, which is responsible for the progression of the disease. Another promising project is a drug for Parkinson's, which is also being tested in clinical trials. The drug targets the accumulation of alpha-synuclein, a protein implicated in the development of Parkinson's. Denali Therapeutics aims to develop new therapies for neurodegenerative diseases to improve the lives of patients. The company is committed to answering the many unanswered medical questions in the field of neurology and making a contribution to overcoming these serious diseases. Denali Therapeutics is one of the most popular companies on Eulerpool.com.

Denali Therapeutics SWOT Analysis

Strengths

Denali Therapeutics Inc has developed a robust pipeline of innovative therapeutic candidates targeting various neurological diseases. This diverse portfolio positions the company well to address multiple unmet medical needs and capture a significant market share in the neurodegenerative diseases space.

The company is led by a highly experienced management team with a proven track record in the biotechnology industry. Their expertise in drug development, commercialization, and strategic partnerships provides Denali Therapeutics with strong leadership and guidance for achieving its objectives.

Weaknesses

Denali Therapeutics relies heavily on external collaborations for the development and commercialization of its therapeutic candidates. While partnerships can bring valuable resources and expertise, they also pose a risk of delays, conflicts of interest, and potential limitations in the company's control over its own products.

As a relatively young company, Denali Therapeutics has limited experience in the commercialization of pharmaceutical products. Successfully bringing candidates to market and navigating the complex regulatory and market access landscape can be challenging, requiring additional resources and expertise in marketing, distribution, and pricing strategies.

Opportunities

The prevalence of neurodegenerative diseases, such as Alzheimer's and Parkinson's, is increasing globally. This presents a significant market opportunity for Denali Therapeutics to address the growing demand for effective treatments. By leveraging its pipeline and focusing on targeted therapies, the company can tap into this expanding market.

Advancements in genetic research have provided deeper insights into the underlying causes of neurodegenerative diseases. Denali Therapeutics can capitalize on these discoveries by developing therapies that target specific genetic mutations or dysfunctions, potentially offering personalized medicine solutions and differentiation from competitors.

Threats

The biotechnology industry is highly competitive, with numerous companies competing for limited market share and investment. Denali Therapeutics faces the risk of intense competition from both established pharmaceutical companies and emerging biotech startups, which may have similar development programs and resources.

The regulatory approval process for pharmaceutical products, especially in the field of neurodegenerative diseases, can be complex and time-consuming. Delays or failures to obtain regulatory approvals could significantly impact Denali Therapeutics' ability to bring its therapies to market. In addition, reimbursement challenges and pricing pressures may affect the commercial success and accessibility of the company's products.

Denali Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Denali Therapeutics Revenue by Segment

Segmente202320222021202020192018
Peripheral Program License-10 M USD15 M USD---
Retained Activities---969,000 USD--
Alzheimer's Disease Services----358,000 USD60,000 USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Denali Therapeutics Revenue by Segment

Segmente202320222021202020192018
ATV:Abeta Program License288.9 M USD-----
CNS program license-----73.93 M USD
CNS Program License25 M USD40 M USD----
Collaboration Agreement Services-51.92 M USD----
Peripheral program license-----47.15 M USD
Takeda Collaboration Agreement Services--19.92 M USD---
PTV:PGRN Collaboration Agreement10 M USD-5 M USD---
Option Research Services1.62 M USD3.15 M USD3.74 M USD---
ATV:TREM2 Collaboration Agreement--5 M USD---
Retained Activities-----2.34 M USD
Collaborative Arrangement, ATV:TREM2------
Collaborative Arrangement, PTV:PGRN------
LRRK2 Program License------

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Denali Therapeutics Revenue by Segment

Segmente202320222021202020192018
LRRK2 Program License---306.55 M USD--
Option Research Services---892,000 USD--
CNS Program License------

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Denali Therapeutics Revenue by Segment

Segmente202320222021202020192018
Retained Activities----10.39 M USD-
Peripheral Product----10 M USD-
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Denali Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Denali Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Denali Therapeutics shares outstanding

The number of shares was Denali Therapeutics in 2023 — This indicates how many shares 137.371 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Denali Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Denali Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Denali Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Denali Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Denali Therapeutics.

Denali Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.63 -0.63  (-0.49 %)2024 Q3
6/30/2024-0.7 -0.59  (15.61 %)2024 Q2
3/31/2024-0.72 -0.78  (-8.8 %)2024 Q1
12/31/2023-0.82 -0.86  (-4.84 %)2023 Q4
9/30/2023-0.82 -0.72  (12.03 %)2023 Q3
6/30/2023-0.7 1.3  (286.35 %)2023 Q2
3/31/2023-0.72 -0.8  (-11.37 %)2023 Q1
12/31/2022-0.81 -0.75  (6.94 %)2022 Q4
9/30/2022-0.82 -0.84  (-2.15 %)2022 Q3
6/30/2022-0.56 -0.48  (14.3 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Denali Therapeutics stock

Eulerpool World ESG Rating (EESG©)

80/ 100

🌱 Environment

91

👫 Social

99

🏛️ Governance

51

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees54
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Denali Therapeutics shareholders

%
Name
Stocks
Change
Date
9.56337 % Baillie Gifford & Co.13,763,596-277,6326/30/2024
8.86004 % Biogen Inc12,751,365-558,87812/31/2023
7.84331 % The Vanguard Group, Inc.11,288,093344,1466/30/2024
6.86374 % BlackRock Institutional Trust Company, N.A.9,878,297577,2766/30/2024
6.82585 % Wellington Management Company, LLP9,823,7671,553,8186/30/2024
4.99718 % Fidelity Management & Research Company LLC7,191,9456,957,0758/12/2024
4.95173 % Capital Research Global Investors7,126,5331,076,5766/30/2024
3.96494 % Temasek Holdings Pte. Ltd.5,706,34506/30/2024
3.30790 % Crestline Investors, Inc.4,760,732-450,0006/30/2024
3.08143 % State Street Global Advisors (US)4,434,790-1,889,0826/30/2024
1
2
3
4
5
...
10

Denali Therapeutics Executives and Management Board

Mr. Ryan Watts

(47)
Denali Therapeutics President, Chief Executive Officer, Director (since 2015)
Compensation 9.28 M

Dr. Alexander Schuth

(49)
Denali Therapeutics Chief Financial Officer, Chief Operating Officer, Company Secretary (since 2022)
Compensation 5.69 M

Dr. Carole Ho

(50)
Denali Therapeutics Chief Medical Officer
Compensation 5.69 M

Mr. Steven Krognes

(54)
Denali Therapeutics Director
Compensation 4.32 M

Mr. Erik Harris

(53)
Denali Therapeutics Independent Director
Compensation 703,311
1
2
3

Most common questions regarding Denali Therapeutics

What values and corporate philosophy does Denali Therapeutics represent?

Denali Therapeutics Inc represents a strong commitment to scientific innovation and the development of transformative therapies for neurodegenerative diseases. With a focus on precision medicine and antibody-based therapies, Denali aims to improve the lives of patients by targeting the underlying causes of these devastating conditions. The company's corporate philosophy revolves around collaboration, integrity, and a patient-centric approach. Denali Therapeutics Inc is dedicated to advancing research, leveraging cutting-edge technologies, and forging strategic partnerships to bring about meaningful advancements in the treatment of neurodegenerative disorders.

In which countries and regions is Denali Therapeutics primarily present?

Denali Therapeutics Inc is primarily present in the United States. With headquarters in South San Francisco, California, the company operates mainly in its home country. As a biotechnology company focused on neurodegenerative diseases, Denali Therapeutics Inc conducts research and development activities within the United States, collaborating with various academic institutions, healthcare professionals, and industry partners nationwide. The company's commitment to advancing therapies for conditions like Alzheimer's and Parkinson's disease is largely focused on the American market, with potential expansion opportunities in the future.

What significant milestones has the company Denali Therapeutics achieved?

Denali Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in December 2017, raising approximately $250 million in proceeds. Additionally, Denali has formed several strategic collaborations with prominent pharmaceutical companies, including Sanofi and Takeda, to accelerate the development of innovative therapies for neurodegenerative diseases. Denali's productive research and drug discovery efforts led to the advancement of several promising drug candidates into clinical trials. The company also received Fast Track designation from the U.S. FDA for its investigational therapy targeting a genetic form of ALS. Denali Therapeutics continues to make impressive progress in its mission to discover and develop effective treatments for neurodegenerative diseases.

What is the history and background of the company Denali Therapeutics?

Denali Therapeutics Inc is a biotechnology company focused on developing therapies for neurodegenerative diseases. Founded in 2015, the company is headquartered in South San Francisco, California. Denali's approach combines proprietary drug delivery technologies with their deep understanding of neurodegenerative diseases. With a mission to defeat neurodegeneration, Denali Therapeutics undertakes rigorous research and development to address diseases like Alzheimer's, Parkinson's, and ALS. By leveraging their innovative portfolio and strategic partnerships, Denali Therapeutics aims to bring effective treatments to patients in need, ultimately improving the quality of life for individuals affected by neurodegenerative disorders.

Who are the main competitors of Denali Therapeutics in the market?

The main competitors of Denali Therapeutics Inc in the market include Biogen Inc., Ionis Pharmaceuticals Inc., and Voyager Therapeutics Inc. These companies are actively engaged in the development and commercialization of innovative therapies in the field of neurodegenerative diseases, emphasizing the treatment of conditions such as Parkinson's disease and Alzheimer's disease. Through their robust research and development efforts, these competitors pose a significant challenge to Denali Therapeutics Inc's goal of providing effective and groundbreaking solutions for patients suffering from neurodegenerative disorders.

In which industries is Denali Therapeutics primarily active?

Denali Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Denali Therapeutics?

Denali Therapeutics Inc is a biotechnology company that focuses on the development and commercialization of therapeutics for neurodegenerative diseases. They employ a unique business model that combines rigorous scientific research with strategic partnerships and collaborations. By leveraging their expertise in the field of neuroscience, Denali Therapeutics aims to identify and target key pathways involved in neurodegenerative diseases, such as Alzheimer's and Parkinson's. Their goal is to develop innovative therapies that can potentially slow down or even halt disease progression, ultimately improving patients' lives. With a strong emphasis on research and development, Denali Therapeutics strives to bring novel treatment options to patients in need.

What is the P/E ratio of Denali Therapeutics 2024?

The Denali Therapeutics P/E ratio is -7.19.

What is the P/S ratio of Denali Therapeutics 2024?

The Denali Therapeutics P/S ratio is 281.3.

What is the Quality Investing of Denali Therapeutics?

The Quality Investing for Denali Therapeutics is 1/10.

What is the revenue of Denali Therapeutics 2024?

The expected Denali Therapeutics revenue is 10.48 M USD.

How high is the profit of Denali Therapeutics 2024?

The expected Denali Therapeutics profit is -409.79 M USD.

What is the business model of Denali Therapeutics

Denali Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of neurodegenerative diseases. The company is based in South San Francisco, California and was founded in 2015. Denali Therapeutics' business model is based on the exploration of novel drugs targeting a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis (ALS), and frontotemporal dementia. The company works closely with clinicians, pharmacy manufacturers, and scientists to develop more innovative and effective therapeutic approaches for these severe conditions. Denali Therapeutics has directed its development platform towards various main areas, including the discovery and development of novel treatment approaches such as antibodies and specific drugs targeting abnormal proteins such as tau, alpha-synuclein, and huntingtin. The company also focuses on gene therapies to combat genetic defects leading to neurodegenerative diseases. Additionally, the company has developed small molecules that prevent protein aggregation in cells. Currently, Denali Therapeutics has three main products in its pipeline. One of them is DNL747, which activates a key receptor in the brain that can help reduce inflammatory reactions associated with a variety of neurodegenerative and autoimmune diseases. DNL758 is a clinically tested selective inhibitor of receptor-interacting protein kinases (RIPK) developed for the treatment of Alzheimer's disease. Finally, DNL310 is specifically designed to protect the brains of patients with Gaucher's disease or Parkinson's disease. The company is likely to generate solid revenues in the near future. In April 2021, Denali Therapeutics reported positive safety data and signaling measurements from Phase 1B/2A studies of their main product, an LRRK2 inhibitor, in Parkinson's disease patients, which could potentially indicate clinical efficacy. Denali Therapeutics also leverages potential partnerships that can cover the entire value chain from research and development to commercialization. In 2018, Denali Therapeutics entered a partnership with Takeda Pharmaceutical, a Japanese pharmaceutical company, to further explore and develop therapeutics for neurodegeneration. Another significant strategic partner of Denali Therapeutics is Sanofi, a global biopharmaceutical company that contracted the company in October 2020 to develop their customized antibodies against neurodegeneration. Overall, Denali Therapeutics is focused on developing and distributing groundbreaking therapies for severe neurodegenerative diseases. In the future, Denali Therapeutics remains a promising player in the field of neurodegeneration with real market prospects.

What is the Denali Therapeutics dividend?

Denali Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Denali Therapeutics pay dividends?

The dividend cannot currently be calculated for Denali Therapeutics or the company does not pay out a dividend.

What is the Denali Therapeutics ISIN?

The ISIN of Denali Therapeutics is US24823R1059.

What is the Denali Therapeutics WKN?

The WKN of Denali Therapeutics is A2H9G8.

What is the Denali Therapeutics ticker?

The ticker of Denali Therapeutics is DNLI.

How much dividend does Denali Therapeutics pay?

Over the past 12 months, Denali Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Denali Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Denali Therapeutics?

The current dividend yield of Denali Therapeutics is .

When does Denali Therapeutics pay dividends?

Denali Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Denali Therapeutics?

Denali Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Denali Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Denali Therapeutics located?

Denali Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Denali Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Denali Therapeutics from 12/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/22/2024.

When did Denali Therapeutics pay the last dividend?

The last dividend was paid out on 12/22/2024.

What was the dividend of Denali Therapeutics in the year 2023?

In the year 2023, Denali Therapeutics distributed 0 USD as dividends.

In which currency does Denali Therapeutics pay out the dividend?

The dividends of Denali Therapeutics are distributed in USD.

All fundamentals about Denali Therapeutics

Our stock analysis for Denali Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Denali Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.